Latest news
GYRE: Net loss widened to $32.8 million on $53.5 million revenue, with strong liquidity maintained - TradingViewTradingView · Fri, 07 Aug 2026 21:03:24 GMTGYRE: Q2 2026 revenue reached $29.1M, net loss widened, and Cullgen acquisition expanded the pipeline - TradingViewTradingView · Fri, 07 Aug 2026 12:06:56 GMTGyre Therapeutics reports Q2 2026 revenue $29.1M, GAAP EPS $(0.12); full-year revenue guidance affirmed - TradingViewTradingView · Fri, 07 Aug 2026 12:03:01 GMT